Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher™) in patients with diffuse somatostatin receptor positive liver metastases

Cancer Biotherapy and Radiopharmaceuticals

Volumn 18, Issue 4, 2003, Pages 581-588

  Bushnell, David ^a,b   Menda, Yusuf ^b   Madsen, Mark ^b   O'Dorisio, Thomas ^b   Carlisle, Thomas ^a,b   Zehr, Pamela ^b   Ponto, Laura ^b   Karwal, Mark ^b   Parker, Stan ^a   Ponto, James ^b   Connolly, Mary ^c   Bouterfa, Hakim ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Liver metastases; Neuroendocrine tumors; OctreoTher

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; OCTREOTHER; OCTREOTIDE; OCTREOTIDE[1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSYL 3 YTTRIUM Y 90]; PENTETREOTIDE; PENTETREOTIDE IN 111; SMT 487 Y 90; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; LIVER SCINTISCANNING; LIVER TOXICITY; MALE; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; RADIATION INJURY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME;

ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ANALYSIS OF VARIANCE; ASPARTATE AMINOTRANSFERASES; CARCINOMA, NEUROENDOCRINE; CLINICAL PROTOCOLS; DISEASE PROGRESSION; HUMANS; LIVER; LIVER NEOPLASMS; OCTREOTIDE; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; YTTRIUM RADIOISOTOPES;

EID: 10744231459     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497803322287664     Document Type: Article

References (15)

1. Jensen R, Doherty G. Carcinoid tumors and carcinoid syndrome. In: DeVita V (ed), Cancer: Principles and Practice of Oncology, 6th ed. Philadelphia, PA, Lippincott, Williams and Wilkins, 2001.
2. Otte A, Hermann R, Heppeler A, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nuc Med 1999;26:1439.
3. 3-Octreotide: Preliminary report in cancer patients. Cancer Biother Radiopharm 1999;14:477.
4. 90Y-DOTATOC) in the treatment of neuroendocrine tumors: A clinical phase II study. Ann Oncol 2001;12:941.
5. 90Y-DOTATOC. Eur J Nucl Med 1000;26:877.
6. Hammond PJ, Wade AF, Gwilliam AM, et al. Amino acid infusion blocks renal tubular uptake of an indium-labeled somatostatin analogue. Br J Cancer 1993;67:1437.
7. Valkema R, De Jong M, Kooij P, et al. Effective and safe inhibition of renal uptake of radiolabeled peptides by combined lysine and arginine infusion. J Nucl Med (Suppl) 2001;42:37P.
8. 111 labeled DOTA-Tyr3-Octreotide (DOTATOC) in patients with neuroendocrine tumors. J Nucl Med 1998;39:221P.
9. Emami B, Lyman J, Brown A. Tolerance of normal tissue to therapeutic irradiation. Int J Rad Oncol Biol Phys 1991;21:109.
10. Siegel JA, Stabin MG. Absorbed fractions for electrons and beta particles in spheres of various sizes. J Nucl Med 1994;35:152.
11. Watkins K, Curley S. Liver and bile ducts. In: Abeloff M (ed), Clinical Oncology, 2nd ed. London, England, Churchill Livingstone, 2000.
12. Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 1995;31:1237.
13. McGinn CJ, Ten Haken RK, Ensminger WD, Walker S, Wang S, Lawrence TS. Treatment of intrahepatic cancers with radiation doses based on a normal tissue complication probability model. J Clin Oncol 1998;16:2246.
14. Cheng JC, Wu JK, Huang CM et al. Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: Dosimetric analysis and implication. Int J Radiat Oncol Biol Phys 2002;54:156.
15. Cheng JC, Wu JK, Huang CM et al. Radiation-induced liver disease after radiotherapy for hepatocellular carcinoma: Clinical manifestation and dosimetric description. Radiother Oncol 2002;63:41.